Open AccessPB1820: CD47‐BLOCKER TTI‐622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53‐MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53‐WILDTYPE AML
Author(s) -
Daver N.,
Maris M.,
Ramchandren R.,
Bixby D.,
Doucette K.,
Mawad R.,
Egan D.,
Stevens D.,
Zonder J.,
Molloy N.,
Scheuber A.,
Bruns I.,
Mantzaris I.,
Konopleva M.,
Goldberg A. D.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850132.55221.5c
Subject(s) - venetoclax , azacitidine , cd47 , medicine , myeloid leukemia , myeloid , hypomethylating agent , leukemia , cancer research , oncology , minimal residual disease , immunology , chronic lymphocytic leukemia , biology , receptor , gene expression , dna methylation , gene , biochemistry